Incretin receptors, comprising the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR), are key components of the glucoregulatory system due to their capacity to prevent postprandial hyperglycemia by amplifying insulin secretion from pancreatic beta cells in a glucose-dependent manner (1). The gene discussed is GLP1R; the disease is Hyperglycemia.